Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases DOI
Samantha Flores-Treviño, Paola Bocanegra‐Ibarias, Daniel Salas‐Treviño

et al.

Expert Opinion on Biological Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 26, 2025

The microbiota composition in humans varies according to the anatomical site and is crucial for maintaining homeostasis an overall healthy state. Several gastrointestinal, vaginal, respiratory, skin diseases are associated with dysbiosis. Alternative therapies such as transplantation can help restore normal be implemented treat clinically relevant diseases. Current conducted clinical trials were included this review (after searching on MEDLINE database from years 2017 2025) fecal (FMT) against recurrent Clostridiodes difficile infection (rCDI) vaginal (VMT) bacterial vaginosis. Washed (WMT) live biotherapeutic products (LBPs) also reviewed. In microbiota-based therapy, selecting optimal donors a limitation. A stool or bank should overcome time-consuming expensive process of donor recruitment. Microbiota-based LBPs promising treatment alternatives rCDI other dysbiosis-associated Specific could engineered out fluids-derived strains achieve selection specific beneficial microorganisms Personalized treatments solutions diseases, which remains important necessity practice.

Language: Английский

Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases DOI
Samantha Flores-Treviño, Paola Bocanegra‐Ibarias, Daniel Salas‐Treviño

et al.

Expert Opinion on Biological Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 26, 2025

The microbiota composition in humans varies according to the anatomical site and is crucial for maintaining homeostasis an overall healthy state. Several gastrointestinal, vaginal, respiratory, skin diseases are associated with dysbiosis. Alternative therapies such as transplantation can help restore normal be implemented treat clinically relevant diseases. Current conducted clinical trials were included this review (after searching on MEDLINE database from years 2017 2025) fecal (FMT) against recurrent Clostridiodes difficile infection (rCDI) vaginal (VMT) bacterial vaginosis. Washed (WMT) live biotherapeutic products (LBPs) also reviewed. In microbiota-based therapy, selecting optimal donors a limitation. A stool or bank should overcome time-consuming expensive process of donor recruitment. Microbiota-based LBPs promising treatment alternatives rCDI other dysbiosis-associated Specific could engineered out fluids-derived strains achieve selection specific beneficial microorganisms Personalized treatments solutions diseases, which remains important necessity practice.

Language: Английский

Citations

0